THE CENTER

The Dutch Biomarker Development Center (BDC) is an initiative of the University of Groningen (RUG), the University Medical Center Groningen (UMCG), the Erasmus Medical Center Rotterdam (EMC), the Radboud University Medical Center Nijmegen (RUMC) and Netherlands Organisation for Applied Scientific Research (TNO). The BDC focuses on biomarker verification and validation in a multi-centric setting involving technology-oriented and clinical centers. The major disease areas are Chronic Obstructive Pulmonary Disease (COPD), Diabetes Type II and Alzheimer’s Disease.

NEWS

LC-MS method to quantify Surfactant Protein D (SPD) in serum

BDC researchers at the University of Groningen have developed a validated LC-MS method to quantify the COPD biomarker SPD in serum. This is the first alternative method to a widely used ELISA assay that has so far been the only way to quantify SPD in complex biological samples. The method is based on immunoaffinity enrichment of SPD in a microtiterplate format, as initially described for the soluble receptor of advanced glycation endproducts (sRAGE) by the same researchers. The work has been published in the journal Talanta. Read the article here. (Posted on 21 June 2019)

Congratulations to Frank Klont

Frank Klont, a member of the BDC project team in Groningen, received his PhD with mention cum laude for his work on ''Mass spectrometry-based methods for protein biomarker quantification: On the road to clinical implementation''. Frank's work focussed on developing high-sensitivity LC-MS methods for a number of COPD biomarkers with emphasis on the soluble receptor of advanced glycation endproducts (sRAGE). The thesis can be found here. (Posted on 10 March 2019)

Groningen researchers identify acute exposure to cigarette smoke as critical preanalytical factor when measuring sRAGE in serum

In a study comparing the effect of smoking three research cigarettes 2 hours prior to sampling, BDC researchers at the University of Groningen show that sRAGE may be decreased by as much as 50%. This effect lasts for at least 24 hours. This critical preanalytical factor, which has so far not been considered in studies on sRAGE as a COPD biomarker, may explain why studies relating sRAGE levels to lung function decline and emphysema development show certain inconsistencies. Taking acute smoke exposure into account may improve reliability of sRAGE as a biomarker. The work has been published in the American Journal of Respiratory Disease and Critical Care Medicine. Read the article here. (Posted on 07 January, 2019)

LC-MS method to quantify sRAGE without the use of affinity ligands

BDC researchers at the University of Groningen have developed a validated LC-MS method to quantify the COPD biomarker sRAGE in serum. The method is based on sRAGE enrichment by strong cation-exchange (SCX) solid-phase extraction (SPE) at pH 10. This is the first time that sRAGE has been quantified in serum without the use of affinity ligands, such as antibodies. It is of interest to note that a comparison of four validated bioanalytical methods (one ELISA and three LC-MS methods) shows a bias with the SCX-SPE-based method giving the highest concentrations. The work has been published in the Analytica Chimica Acta. Read the article here. (Posted on 07 January, 2019)

[News archives]

RUG UMCG EMC RUMC TNO